Ladenburg Thalmann & Co. Inc.

December 15, 2016

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Re: RXI PHARMACEUTICALS CORPORATION

Registration Statement on Form S-1 (Registration No. 333-214199) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg Thalmann & Co., Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by RXi Pharmaceuticals Corporation that the effective date of the above-referenced registration statement be accelerated to 4:05 p.m. (Eastern Time), or as soon as practicable thereafter, on December 15, 2016, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours, LADENBURG THALMANN & CO. INC.
By:	/s/ Nicholas Stergis
	Name: Nicholas Stergis Title: Managing Director